References
- NestleFOKaplanDHBarkerJPsoriasisNEJM2009361549650919641206
- MrowietzUKragballeKReichKDefinition of treatment goals for moderate to severe psoriasis: a European consensusArch Dermatol Res2011303111020857129
- World Health OrganizationThe known health effects of UV [webpage on the Internet] Available at: http://www.who.int/uv/faq/uvhealtfac/en/index1.htmlAccessed November 13, 2014
- EnamandramMKimballABPsoriasis epidemiology: the interplay of genes and the environmentJ Invest Dermatol2013133228728923318785
- ParisiRSymmonsDPGriffithsCEAshcroftDMIdentification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project teamGlobal epidemiology of psoriasis: a systematic review of incidence and prevalenceJ Invest Dermatol2013133237738523014338
- BassukasIDMavridouKAEvangelouTGaitanisGThe prevalence of psoriasis among elderly individuals: more questions than answers [webpage on the Internet]Ageing Res201121 Available at: http://www.pagepress.org/journals/index.php/ar/article/view/ar.2011.e1/html_93Accessed November 13, 2014
- RigopoulosDGregoriouSKatrinakiACharacteristics of psoriasis in Greece: an epidemiological study of a population in a sunny Mediterranean climateEur J Dermatol201020218919520123642
- SamoutisAKaitelidouDSiskouOModerate and severe plaque psoriasis: a quality of life and cost-of-illness study from GreeceIntl J Caring Sci201252
- KyriakisKPPalamarasIPaganaGTerzoudiSEvangelouGLifetime prevalence fluctuations of chronic plaque psoriasis and other non-pustular clinical variantsJ Eur Acad Dermatol Venereol200822121513151418482310
- RahoGKolevaDMGarattiniLNaldiLThe burden of moderate to severe psoriasis: an overviewPharmacoeconomics201230111005101322994598
- JacobsPBissonnetteRGuentherLCSocioeconomic burden of immune-mediated inflammatory diseases – focusing on work productivity and disabilityJ Rheumatol Suppl201188556122045980
- Lewis-BeckCAbouzaidSXieLBaserOKimEAnalysis of the relationship between psoriasis symptom severity and quality of life, work productivity, and activity impairment among patients with moderate-to-severe psoriasis using structural equation modelingPatient Prefer Adherence2013719920523508007
- KimballABGuérinATsanevaMEconomic burden of comorbidities in patients with psoriasis is substantialJ Eur Acad Dermatol Venereol201125215716320561129
- International Federation of Psoriasis AssociationPsoriasis is a serious disease deserving global attention [webpage on the Internet] Available at: http://www.ifpa-pso.org/getfile.ashx?cid=279366&cc=3&refid=18Accessed November 13, 2014
- LiuYWuEQBensimonAGCost per responder associated with biologic therapies for Crohn’s disease, psoriasis, and rheumatoid arthritisAdv Ther201229762063422843208
- PathiranaDOrmerodADSaiagPEuropean S3-guidelines on the systemic treatment of psoriasis vulgarisJ Eur Acad Dermatol Venereol200923Suppl 217019712190
- GiannettiACommentary on the European S3-guidelines on the systemic treatment of psoriasisJ Eur Acad Dermatol Venereol2010243368 author reply 368–36920070453
- PathiranaDNastAOrmerodADOn the development of the European S3 guidelines on the systemic treatment of psoriasis vulgaris: structure and challengesJ Eur Acad Dermatol Venereol201024121458146720456548
- American Academy of Dermatology2008Guidelines of care for the management of psoriasis and psoriatic arthritis Available at: https://www.aad.org/File%20Library/Global%20navigation/Education%20and%20quality%20care/Guidelines-psoriasis-sec-2.pdfAccessed October 15, 2014
- HsuSPappKALebwohlMGNational Psoriasis Foundation Medical BoardConsensus guidelines for the management of plaque psoriasisArch Dermatol201214819510222250239
- ReichKBurdenADEatonJNHawkinsNSEfficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trialsBr J Dermatol2012166117918821910698
- Galván-BanqueriMMarín GilRSantos RamosBBautista PalomaFJBiological treatments for moderate-to-severe psoriasis: indirect comparisonJ Clin Pharm Ther201338212113023442134
- KimIHWestCEKwatraSGFeldmanSRO’NeillJLComparative efficacy of biologics in psoriasis: a reviewAm J Clin Dermatol201213636537422967166
- WeinbergJMAn overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasisClin Ther200325102487250514667953
- TutroneWDSainiRWeinbergJMBiological therapy for psoriasis: an overview of infliximab, etanercept, efalizumab and alefaceptIDrugs200471454914730466
- SainiRTutroneWDWeinbergJMAdvances in therapy for psoriasis: an overview of infliximab, etanercept, efalizumab, alefacept, adalimumab, tazarotene, and pimecrolimusCurr Pharm Des200511227328015638763
- WeinbergJMBottinoCJLindholmJBuchholzRBiologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-cell-targeted therapies efalizumab and alefaceptJ Drugs Dermatol20054554455516167412
- RavalKLoflandJHWatersHPiechCTDisease and treatment burden of psoriasis: examining the impact of biologicsJ Drugs Dermatol201110218919621283925
- LangleyRGEffective and sustainable biologic treatment of psoriasis: what can we learn from new clinical data?J Eur Acad Dermatol Venereol201226Suppl 2212922356632
- SivamaniRKGoodarziHGarciaMSBiologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoringClin Rev Allergy Immunol201344212114022311162
- BakerELColemanCIReinhartKMEffect of Biologic Agents on Non-PASI Outcomes in Moderate-to-Severe Plaque Psoriasis: Systematic Review and Meta-AnalysesDermatol Ther (Heidelb)201221923205332
- KentikelenisAKaranikolosMPapanicolasIBasuSMcKeeMStucklerDHealth effects of financial crisis: omens of a Greek tragedyLancet201137898011457145821988763
- European Medicines AgencyEPAR summary for the public: Humira (adalimumab) [webpage on the Internet] Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000481/WC500050865.pdfAccessed November 13, 2014
- European Medicines AgencyEPAR summary for the public: Enbrel (etanercept) [webpage on the Internet] Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000262/WC500027364.pdfAccessed November 13, 2014
- European Medicines AgencyEPAR summary for the public: Remicade (infliximab) [webpage on the Internet] Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000240/WC500050883.pdfAccessed November 13, 2014
- European Medicines AgencyEPAR summary for the public: Stelara (ustekinumab) [webpage on the Internet] Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000958/WC500058509.pdfAccessed November 13, 2014
- Ministry of Health, price bulletin 81505/30-08-2013, YA Available at: http://www.moh.gov.gr/articles/times-farmakwn/deltia-timwn/1860-diorthwtiko-deltio-timwn-30-08-2013Accessed August 10, 2013 Greek
- MauskopfJASullivanSDAnnemansLPrinciples of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices – budget impact analysisValue Health200710533634717888098
- LebwohlMPsoriasisLancet200336193641197120412686053
- SchonMPBoehnckeWHPsoriasisNEJM2005352181899191215872205
- NijstenTMargolisDJFeldmanSRRolstadTSternRSTraditional systemic treatments have not fully met the needs of psoriasis patients: results from a national surveyJ Am Acad Dermatol2005523 Pt 143444415761421
- ArmstrongAWHarskampCTArmstrongEJThe association between psoriasis and obesity: a systematic review and meta-analysis of observational studiesNutr Diabetes20122e5423208415
- NastABoehnckeWHMrowietzUDeutsche Dermatologische Gesellschaft (DDG); Berufsverband Deutscher Dermatologen (BVDD)S3 – Guidelines on the treatment of psoriasis vulgaris (English version). UpdateJ Dtsch Dermatol Ges201210Suppl 2S1S95
- SmithCHAnsteyAVBarkerJN(Chair of Guideline Group)British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009Br J Dermatol20091615987101919857207
- MenterAGottliebAFeldmanSRGuidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologicsJ Am Acad Dermatol200858582685018423260
- BrezinskiEAArmstrongAWOff-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapyPLoS One201274e3348622509259
- VillacortaRHayJWMessaliACost effectiveness of moderate to severe psoriasis therapy with etanercept and ustekinumab in the United StatesPharmacoeconomics201331982383923975739
- AhnCSGustafsonCJSandovalLFDavisSAFeldmanSRCost effectiveness of biologic therapies for plaque psoriasisAm J Clin Dermatol201314431532623696234
- NelsonAAPearceDJFleischerABJrBalkrishnanRFeldmanSRCost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment periodJ Am Acad Dermatol200858112513517996329
- FerrándizCGarcíaABlascoAJLázaroPCost-efficacy of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasisJ Eur Acad Dermatol Venereol201226676877722126264
- SamarasekeraESawyerLParnhamJSmithCHGuideline Development G. Assessment and management of psoriasis: summary of NICE guidanceBMJ2012345e671223097521
- DrummondMBarbieriMCookJTransferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force reportValue Health200912440941819900249
- IannazzoSDe FrancescoMGomez-UlloaDBenucciMA review of cost-effectiveness evaluations as part of national health technology assessments of biologic DMARDs in the treatment of rheumatoid arthritisExpert Rev Pharmacoecon Outcomes Res201313445546823977974
- Salmon-CeronDTubachFLortholaryORATIO groupDrug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registryAnn Rheum Dis201170461662321177290
- TubachFSalmonDRavaudPResearch Axed on Tolerance of Biotherapies GroupRisk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registryArthritis Rheum20096071884189419565495
- MarietteXTubachFBagheriHLymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registryAnn Rheum Dis201069240040819828563
- PiasericoSContiALo ConsoleFEfficacy and safety of systemic treatments for psoriasis in elderly patientsActa Derm Venereol201494329329724158307
- TohSLiLHarroldLRComparative safety of infliximab and etanercept on the risk of serious infections: does the association vary by patient characteristics?Pharmacoepidemiol Drug Saf201221552453422411435
- PearceDJHigginsKBStealeyKHAdverse events from systemic therapies for psoriasis are common in clinical practiceJ Dermatolog Treat200617528829317092859
- SiztoSBansbackNFeldmanSRWillianMKAnisAHEconomic evaluation of systemic therapies for moderate to severe psoriasisBr J Dermatol200916061264127219120346
- National Institute for Health and Clinical ExcellencePsoriasis: The assessment and management of psoriasis Available at: https://www.nice.org.uk/guidance/cg153/resources/guidance-psoriasis-pdfAccessed October 15, 2014
- FragoulakisVKourlabaGGoumenosDKonstantoulakisMManiadakisNEconomic evaluation of intravenous iron treatments in the management of anemia patients in GreeceClinicoecon Outcomes Res2012412713422629113
- AvgerinouGBassukasIChaidemenosGBudget impact analysis of ustekinumab in the management of moderate to severe psoriasis in GreeceBMC Dermatol2012121022831458